The Atlas of MS showed that off-label disease-modifying therapies are used in at least 89 countries. This highlights the need for structured and transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions. The authors put forward general principles for the ethical use of off-label DMTs for treating MS and a process to assess existing evidence and develop recommendations for their use in this manuscript.

The principles and process are endorsed by the World Federation of Neurology (WFN), American Academy of Neurology (AAN), European Academy of Neurology (EAN), Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Middle-East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) and Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS).

Research led by investigators at The Ohio State University Wexner Medical Center provides new hope for recovery from degenerative neurological diseases, such as multiple sclerosis.
Using a mouse model, researchers at Ohio State and the University of Michigan discovered a new type of immune cell that not only rescues damaged nerve cells from death but partially reverses nerve fiber damage. The research team also identified a human immune cell line, with similar characteristics, that promotes nervous system repair.

Learn more here: 

To all our volunteers, we appreciate all you do!
National Volunteer Week April 19-25, 2020. 

Volunteer Appreciation

Association Forum awarded ACTRIMS Managing Director, Jen Brydges, the prestigious Forty Under 40 award for her commitment to the industry, leadership skills and continued potential. Congratulations Jen!

New Chair Aims to Keep ACTRIMS Up to Pace with Dynamism of the Multiple Sclerosis Field

Dr. Jeffrey Cohen on ACTRIMS Forum 2019 and trends in the subspecialty.

Read more.

Spinal cord atrophy found to be accelerated in subset of RRMS patients

DALLAS – The rate of spinal cord atrophy at the C1 level is promising as a prognostic biomarker for the future conversion to secondary progressive disease in patients with relapsing remitting multiple sclerosis (RRMS), results from a novel, single-center study suggest.

Read More.

Smartphone-based visual tests for MS patients show promise

DALLAS – A battery of smartphone-based tests has been developed to help detect visual pathway disturbances in MS patients and to follow them over time.

Read more.

Large survey reveals that few MS patients have long-term care insurance

DALLAS – A number of sociodemographic factors may influence health and disability insurance access by individuals with multiple sclerosis, including employment, age, gender, disease duration, marital status, and ethnicity, results from a large survey suggest.

Read more